FilingReader Intelligence
Pfizer India launches 20-valent pneumococcal vaccine for adults
August 11, 2025 at 02:09 PM UTC•By FilingReader AI
Pfizer Limited launched its 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV20) for adults in India on August 11, 2025.
The single-shot vaccine provides protection against 20 serotypes of Streptococcus pneumoniae and is approved for adults aged 18 years and older. It offers wider serotype coverage than previous conjugate vaccines available in India.
According to managing director Meenakshi Nevatia, the launch addresses increasing demand for adult immunization in the country.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:PFIZER•Bombay Stock Exchange
News Alerts
Get instant email alerts when Pfizer publishes news
Free account required • Unsubscribe anytime